Genfleet Therapeutics

• NCT07846358

  Phase 1/2, Not yet recruiting, 84 people, 29 Sept 2026

• A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation

  Phase 1/2, Recruiting, 222 people, 1 Jul 2026

• NCT07262567

  Phase 3, Recruiting, 320 people, 3 Dec 2025

• NCT05386888

  Phase 2, Completed, 65 people, 23 May 2022

Sources: clinicaltrials.gov

• Innovent Biologics

  Collaboration, 2 Sept 2021

Sources: www1.hkexnews.hk